The financial market is a machine supported by converting opinions, and when the Federal Reserve announced the latest reduction in interest rates, these opinions pushed the capital to health and financial stocks.
Hims & her health today
Hims & Rels Health
As of 09/19/2025 03:59 pm
- 52 weeks
- 15.73 dollars
▼
72.98 dollars
- P/E ratio.
- 72.18
- The target price
- $ 38.92
This type of sector rotation signals, where investors sees flexibility and opportunity.
One name sits at the intersection of health care and technology HIMS & Her Health Inc. NYSE: HIMS.
It is a stable stock in 2025: Some see it as full-time because of its GLP-1 weight loss treatments, while others think it has just started.
With a strong quarterly results and a climb solution coverage, investors may want to reassess the place where Hims stands – and its location.
Growth is difficult to ignore
when SPDR health care box SPDR Nysearca: xlv About 1 % rose on the day of the Federal Reserve, hinting on a journey to stability. This is also when Hims & HERS started showing her hand.
In the latest Q2 2025 profitsThe company mentioned 544.8 million dollars in revenue73 % increase compared to the previous year. More importantly, the net subscribers amounted to 2.4 million, an increase of 31 % over the previous year. For the subscription -based platform, this type of growth is not only attractive, but it is very important.
The average revenue for each user from $ 57 in 2024 to $ 74 in 2025, increased 30 %, indicating improving deeper retainment and spending, enhancing revenues and evaluation.
It is distinguished. Hims & Hers is trading in a The price ratio to the book (P/B) from 25.9XAerobic over the average medical sector of 13.6X. This type of evaluation usually appears only when the market believes that growth is real and sustainable.
The most prominent canaccord $ 68 is the budget feelings of analysts
Despite its 52 -week trading, Wall Street is still divided. the The purpose of the consensus is $ 38.92This means about 33 % of the negative side of the last prices. This consensus is likely to reflect a cautious view that depends on the fluctuation of stocks instead of the basics.
But not all analysts agree.
Maria Ripps from Canacord Genuity recently repeated the purchase rating and set $ 68 the target price On stocks. This means that there are 17 % of the current levels-and it is placed at an amazing distance from its highest level in 52 weeks less than $ 73.
Given the company’s last increase by 32.9 %, this goal does not seem to be out of reach. The gathering appears to be driven by strong profits and optimism to the investor about the low interest rates that feed the re -investment and expansion in the future.
Hims & HERS Health, Inc.
GPS before the market
If the Ripps is correct, and if more analysts follow, the current price may represent a chance window. HIMS & HERS works in a sweet place in the market: frequent revenue, increasing customer base, increasing spending for each user, and the basic system that measures.
Those who go up in the field of health care and digital care should also think about how to accumulate HIMS against its competitors.
Although the risks, regulatory and operational alike, are large, the strong basics of the company and market momentum justify the evaluation.
HIMS & HERS HEELTH: strong Q2 results
HIMS & HERS Health is no longer just a speculative play. With strong growth for subscribers, improving margins, and a scale designed business model, he began to obtain their evaluation premium.
If you are waiting for the concept proof, the Q2 may have just delivered it. And if analysts’ morale turns in line with the CANACCORD of $ 68, this stock may have more space for operation.
Before you think about his health and health, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … Hims & HERS Health was not in the list.
While Hims & HERS Health currently has a decrease between analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Marketbeat analysts just released the best five short plays in October 2025. Learn the stocks that have the most short interest and how to trade. Enter your email address to know the companies that have set the list.
